Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9559517 | 0.85 | ALDH1A1 (0.58) | TSHRGPR35ALDH1A1TDP1HSD17B10 | |
| SCHEMBL29872530 | 0.85 | ALDH1A1 (0.58) | TSHRGPR35ALDH1A1TDP1HSD17B10 | |
| SCHEMBL472796 | 0.84 | TSHR (0.55) | TSHRGPR35ALDH1A1TDP1HSD17B10 | |
| SCHEMBL31108747 | 0.83 | GPR35 (0.56) | TSHRGPR35ALDH1A1TDP1HSD17B10 | |
| SCHEMBL4958698 | 0.83 | GPR35 (0.60) | TSHRGPR35ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL16974400 | 0.83 | GPR35 (0.60) | TSHRGPR35ALDH1A1CYP3A4SMN1; SMN2 | |
| Methyl Alcohol SCHEMBL28765881 | 0.82 | TSHR (0.62) | TSHRGPR35ALDH1A1TDP1HSD17B10 | |
| SCHEMBL1369143 | 0.82 | GPR35 (0.54) | TSHRGPR35ALDH1A1TDP1HSD17B10 | |
| SCHEMBL28740174 | 0.82 | ALDH1A1 (0.54) | TSHRGPR35ALDH1A1TDP1CYP3A4 | |
| SCHEMBL58062 | 0.81 | TSHR (0.67) | TSHRGPR35ALDH1A1TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4514261-A | Refining of tertiary butylstyrene | EL PASO PRODUCTS COMPANY (US) | 1985-04-30 | — | — | US | claimed |
| US-4482769-A | Reducing 2,4-dinitroortho-cresol in effluent stream from dinitrotoluene process | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1984-11-13 | — | — | US | claimed |
| EP-4602020-A1 | ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING | Ecolab USA, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025059441-A1 | ANTIPOLYMERANT COMPOSITIONS WITH BENZOQUINONE OR NAPHTHOQUINONE AND OXYGENATED AMINOPHENOL AND METHODS OF USING | ECOLAB USA INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20250092312-A1 | ANTIPOLYMERANT COMPOSITIONS WITH BENZOQUINONE OR NAPHTHOQUINONE AND OXYGENATED AMINOPHENOL AND METHODS OF USING | ECOLAB USA INC. | 2025-03-20 | — | — | US | disclosed |
| EP-3898566-B1 | HYDROXYLATED QUINONE ANTIPOLYMERANTS AND METHODS OF USING | ECOLAB USA INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240141131-A1 | ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING | ECOLAB USA INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024081354-A1 | ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING | ECOLAB USA INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11866631-B2 | Oxygenated aminophenol compounds and methods for preventing monomer polymerization | ECOLAB USA INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3820846-B1 | COMPOSITION FOR INHIBITING MONOMER POLYMERIZATION COMPRISING A NITROXIDE INHIBITOR, A QUINONE METHIDE RETARDER AND AN AMINE STABILIZER | ECOLAB USA INC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4028382-B1 | QUINONE METHIDE AND AMMONIUM SALT ANTIPOLYMERANT COMPOSITION AND METHOD | ECOLAB USA INC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-0122010-B1 | TIMED RELEASE DELIVERY MEANS FOR DELIVERY OF ACTIVE AGENT TO SPATIALLY SEPARATED TERRAIN LOCATIONS AND COMPOSITIONS COMPRISED THEREBY | METROPOLITAN MOSQUITO CONTROL DISTRICT (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0186270-B1 | TERTIARY BUTYLSTYRENE RECOVERY | EL PASO PRODUCTS COMPANY (A Delaware Corporation) (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0186269-B1 | REFINING OF TERTIARY BUTYLSTYRENE | EL PASO PRODUCTS COMPANY (A Delaware Corporation) (US) | 1988-05-18 | — | — | EP | disclosed |
| EP-0186269-A1 | Refining of tertiary butylstyrene | EL PASO PRODUCTS COMPANY (A Delaware Corporation) (US) | 1986-07-02 | — | — | EP | disclosed |
| EP-0186270-A1 | Tertiary butylstyrene recovery | EL PASO PRODUCTS COMPANY (A Delaware Corporation) (US) | 1986-07-02 | — | — | EP | disclosed |
| US-4543438-A | EXTRACTION WITH SULFONAE-WATER MIXTURE | EL PASO PRODUCTS COMPANY (US) | 1985-09-24 | — | — | US | disclosed |
| US-4543437-A | SOLVENT EXTRACTION WITH SULFOLANE | EL PASO PRODUCTS COMPANY (US) | 1985-09-24 | — | — | US | disclosed |
| US-4514261-A | Refining of tertiary butylstyrene | EL PASO PRODUCTS COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| EP-0122010-A1 | Timed release delivery means for delivery of active agent to spatially separated terrain locations and compositions comprised thereby | METROPOLITAN MOSQUITO CONTROL DISTRICT (US) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866631-B2 | Oxygenated aminophenol compounds and methods for preventing monomer polymerization | HPD, DNPEP, PAH | TSHR 4849/4885GPR35 3009/4885ALDH1A1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.